Reading this on a mobile device? Try our optimized mobile version here:

October 9, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Boston inches closer to title of No. 1 biotech hub
    Boston is becoming the world's biggest biotech hub and will hold that title for a generation, Luke Timmerman writes. The San Francisco Bay area leads in six of seven measures in an Ernst & Young report, while Boston is first in one and second in the others, but those metrics omit private companies and Big Pharma investment. Public investment in land use and transportation will support the scientific infrastructure and yield rewards for Boston for years to come, Timmerman writes. Xconomy (10/8) LinkedInFacebookTwitterEmail this Story
Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenges faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio.
  Health Care & Policy 
  • Ardelyx licenses experimental kidney drugs to AstraZeneca
    Ardelyx granted AstraZeneca exclusive worldwide development rights to its NHE3 inhibitor program, including lead compound RDX5791, which is under clinical development for constipation-predominant irritable bowel syndrome. The firms plan to develop RDX5791 for patients with end-stage renal disease and chronic kidney disease. Under terms of the deal, Ardelyx will get $35 million plus a possible $237.5 million in milestone fees and sales royalties. PharmaTimes (U.K.) (10/8) LinkedInFacebookTwitterEmail this Story
  • Lilly's solanezumab shows promise against Alzheimer's
    Eli Lilly and Co.'s solanezumab slowed memory loss and cognitive decline by approximately 30% in patients with early-stage Alzheimer's disease, showing the first evidence that a drug might prevent progression. The findings support the argument that beta-amyloid targeting benefits patients, said Rachelle Doody, Baylor College of Medicine's chairwoman of Alzheimer's research. Bloomberg Businessweek (10/8) LinkedInFacebookTwitterEmail this Story
  • Sanofi's Zaltrap improves survival in colon cancer trial
    Patients with colon cancer who received Sanofi's Zaltrap, or aflibercept, plus chemotherapy saw significant improvement in overall survival during a late-stage trial. Zaltrap is an anti-angiogenic agent that starves blood tumors. Reuters (10/8) LinkedInFacebookTwitterEmail this Story
Online Biotech Grad Programs from Johns Hopkins
Become a leader in biotechnology with a graduate program from Johns Hopkins AAP. We offer 8 flexible online graduate degrees and certificates ranging from Biotech to Regulatory Science. Gain the expertise necessary to excel in and beyond the lab at a world-renowned university. Learn more.
  Company & Financial News 
  • Gliknik raises $4.9M to advance autoimmune drug candidate
    Gliknik obtained $4.9 million in a Series B funding round, led by Baxter Ventures. The firm will use the proceeds to bring GL-2045, an experimental drug designed to imitate effects of IV immunoglobulin, into clinical development as treatment for autoimmune conditions, including Myasthenia gravis. (10/8) LinkedInFacebookTwitterEmail this Story
  • RXi's retinoblastoma therapy wins $300K federal grant
    The National Cancer Institute awarded RXi Pharmaceuticals a $300,000 grant to support work with the Memorial Sloan-Kettering Cancer Center on the development of an RNAi therapy for retinoblastoma. The goal is to come up with an RNAi treatment that will self-deliver RXi's sd-rxRNA compounds. "The idea is to actually use RNAi to silence the genes in the retina that cause the retinoblastoma to grow. By turning off those genes the tumor basically will not continue to grow and will begin to shrink," said RXi president and CEO Geert Cauwenbergh. Mass High Tech (Boston) (10/5) LinkedInFacebookTwitterEmail this Story
  Global Developments 
  • India and U.S. unite to support biotechnology breakthroughs
    The Washington Biotechnology and Biomedical Association and the Association of Biotechnology Led Enterprises in India have entered an agreement to give members an opportunity to work together and invest in projects in Washington state and India. "The collaboration aims to achieve breakthrough discoveries to provide affordable solutions for critical diseases, important challenges in agriculture and energy on mutually agreed topics," ABLE president P.M. Murali said. The Hindu Business Line (India) (10/7) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  Food & Agriculture 
  Industrial & Environmental 
  • Researcher pitches poplars-to-biofuel idea at Chicago event
    Richard Meilan, an associate professor at Purdue University and a participant in the Midwest Aviation Sustainable Biofuels Initiative, pitched an idea for using biotech poplar trees as a biofuel feedstock at an event sponsored by the Clean Energy Trust in Chicago. Initial tests have shown that the introduction of a corn gene called Corngrass1 results in fast-growing poplars with a lignin structure suited for biofuels, Meilan said. Midwest Energy News (10/8) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

If it's very painful for you to criticize your friends -- you're safe in doing it. But if you take the slightest pleasure in it, that's the time to hold your tongue."
--Alice Duer Miller,
American writer and poet

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information